Navigation Links
Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
Date:8/14/2008

SAN FRANCISCO, Aug. 14 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced financial results for the three and six months ended June 30, 2008.

Net operating loss for the three months ended June 30, 2008 was $3.8 million or $0.16 per share compared to $1.5 million or $0.11 per share, for the same period of 2007. Net operating loss for the six months ended June 30, 2008 totaled $6.8 million or $0.28 per share compared to $2.2 million or $0.16 for the same period of 2007. Weighted average shares outstanding for the three months ended June 30, 2008 and 2007 were 24.1 million and 13.8 million, respectively. For the six months ended June 30, 2008 and 2007, weighted average shares outstanding were 24.1 million and 13.8 million, respectively.

Nile reported no revenue for the three and six months ended June 30, 2008 and 2007, respectively. Research and development expenses were $2.9 million for the three months ended June 30, 2008 compared to $0.9 million for the comparable period of 2007. For the six months ended June 30, 2008, research and development expenses totaled $4.9 million compared with $1.4 million for the same period of 2007. General and administrative expenses were $1.0 million for the three months ended June 30, 2008 compared to $0.6 million for the comparable period of 2007. For the six months ended June 30, 2008, general and administrative expenses totaled $2.2 million compared with $0.7 million for the same period of 2007.

At June 30, 2008, Nile had cash and cash equivalents of $10.3 million compared to $16.2 million on December 31, 2007. This $5.9 million decrease occurred as cash was used for operations.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... DIEGO , May 24, 2013 ... company using proprietary taste science technologies to discover, develop, ... David Linemeyer , Ph.D., the Company,s Vice ... Vice President, Investor Relations & Corporate Communications, will present ... May 31, at 10:25 a.m. Eastern Time (7:25 a.m. ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") ... science-based research and development, sales and marketing of ... announced today that it is awarding exclusive Vestiage ... of Reluma Skin Illuminating Facial Care. Qualified applicants ... sending an email to info(at)vestiageinc(dot)com and putting RELUMA ...
(Date:5/23/2013)... Colo. , May 23, 2013 Venaxis, ... diagnostic company focused on obtaining FDA clearance and commercializing ... today announced the pricing of an underwritten public offering ... warrants to purchase 3,500,000 shares of its common stock ... a combined public offering price of $1.25 per share ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Patheon ... manufacturing services to the global pharmaceutical industry, will host ... Novel Approaches to Testing” on Tuesday, June 4, 2013 ... pharmaceutical manufacturers are required to comply with regulations for ... practices with limited scientific underpinning and little evaluation of ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... SUNNYVALE, Calif., June 24 Cepheid (Nasdaq: CPHD ... Universal Antenatal Screening for Group B Streptococcus, published in ... Medicine concluded that rapid, PCR-based testing at the time of ... streptococcal (GBS) screening over the normal antepartum testing done at ...
... neuropathy, and other conditions caused by a loss of myelin ... adequate treatments do not yet exist. That,s in large part ... issue of the journal Biomaterials , a UCF team ... motor nerves that are insulated and organized the same way ...
... 23 Environmental Tectonics Corporation (OTC Bulletin Board: ETCC) ... Division will be exhibiting at the upcoming Undersea and ... non-profit organization and is the primary source of scientific ... , The 2009 Annual UHMS meeting will be ...
Cached Biology Technology:New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery 2New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery 3New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery 4UCF team's advanced nerve cell system could help cure diabetic neuropathy, related diseases 2UCF team's advanced nerve cell system could help cure diabetic neuropathy, related diseases 3UCF team's advanced nerve cell system could help cure diabetic neuropathy, related diseases 4Environmental Tectonics Corporation's BioMedical Division to Exhibit at Undersea and Hyperbaric Medical Society Meeting 2Environmental Tectonics Corporation's BioMedical Division to Exhibit at Undersea and Hyperbaric Medical Society Meeting 3Environmental Tectonics Corporation's BioMedical Division to Exhibit at Undersea and Hyperbaric Medical Society Meeting 4
(Date:5/24/2013)... microRNAs (miRNAs) and other non-coding RNAs are small ... proteins. In recent years they have emerged as ... establish tissue origin for cancers of unknown primary ... for disease, but clinically tractable, diagnostic methods for ... currently available. In this issue of the ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) discovery ... grasses , Within the genome of each species, ... little change in position and sequence over millions of ... of these evolutionarily stable sequences, so-called conserved noncoding sequences ... genes or the condensation of chromosomes, but the function ...
(Date:5/23/2013)... Health at Emory University, along with partners at ... $4 million grant over four years to establish ... Exposome Research Center: Understanding Lifetime Exposures). The grant ... the United States. , The HERCULES Center ... Health Sciences (NIEHS) of the National Institutes of ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
... plays a crucial for a wide range of physiological ... a protein that functions specifically to extend lifespan and ... response to stress. , "In past experiments, meddling with ... aging and life span inevitably invited a host of ...
... University of Surrey have developed a new technique for ... the development of new medicines and treatments. , Crystallisation ... into three dimensional crystals, thus enabling their atomic structure ... crystals indicates the proteins function, and from this, researchers ...
... research indicates that an area of the brain thought ... in visual processing during which sexual orientation modulates how ... Felicitas Kranz and Alumit Ishai of the University of ... by humans, face recognition is arguably the most developed. ...
Cached Biology News:For the first time: Longevity modulated without disrupting life-sustaining function 2For the first time: Longevity modulated without disrupting life-sustaining function 3Scientists make first step towards 'holy grail' of crystallography 2Face perception is modulated by sexual orientation 2Face perception is modulated by sexual orientation 3Face perception is modulated by sexual orientation 4
... standard for sample concentration and drying. The ... a combination of centrifugal force, heat and vacuum ... , SC210A comes equipped with:, Large ... compatibility , ...
... RC Maxi MB (for aqueous, other low ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
... Bio for vacuum concentrator/centrifugal evaporator systems ... and biochemistry for rapid and safe concentration ... be expanded with pumps, different of cold ... (eliminating sample loss by transfer), ensuring solvent ...
... The Jouan RC10 series of vacuum ... product protection features allied to rapid and ... modules can be combined with oil-free or ... traps and a wide selection of rotors ...
Biology Products: